Upstream Bio, Inc.(UPB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,786 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
UPB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Upstream Bio, Inc. (UPB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UPB at 19.7/100 on a 32-signal composite quality model, placing it at rank #2,786 of 2,962 stocks — the bottom half of the AI-ranked universe. UPB scores in the top quartile across institutional flow (90.5). Areas of concern include free cash flow (0.8) and profitability (0.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Upstream Bio, Inc. reports quarterly revenue of $773.0K, net income of $-39.7M. Top institutional holders of UPB by reported 13-F value include FMR, ORBIMED ADVISORS, NORGES BANK, based on the most recent SEC filings. UPB trades on the Nasdaq exchange and files with the SEC under CIK 2022626. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UPB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Upstream Bio, Inc. directly from SEC EDGAR. Upstream Bio, Inc.'s 13F Pro composite quality score has ranged between 17 and 26 since 2025, currently 19.7 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$773.0K
Net Income
Q2 2026
$-39.7M
ROIC
Q2 2026
-62.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+20.4% YoYNet Income
-128.4% YoYOperating Income
-106.2% YoYEPS (Diluted)
+52.3% YoYTotal Assets
-26.6% YoYOp. Cash Flow
-125.2% YoYFree Cash Flow
-123.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $2.9M +20.4% | $2.4M -0.4% | $2.4M | — |
| Net Income | $-143.4M -128.4% | $-62.8M -205.8% | $-20.5M | — |
| Operating Income | $-160.4M -106.2% | $-77.8M -93.9% | $-40.1M | — |
| EPS (Diluted) | $-2.66 +52.3% | $-5.58 +54.8% | $-12.35 | — |
| Total Assets | $353.8M -26.6% | $481.7M +311.0% | $117.2M | — |
| Operating Cash Flow | $-133.3M -125.2% | $-59.2M -56.0% | $-37.9M | — |
| Free Cash Flow | $-133.4M -123.6% | $-59.7M -56.8% | $-38.1M | — |
Get alerted when UPB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Upstream Bio, Inc. including:
Top Institutional Holders of UPB
FMR LLC
$56.5M8,162,897 shORBIMED ADVISORS LLC
$39.4M5,693,589 shNORGES BANK
$26.1M3,768,619 shBlackRock, Inc.
$26.0M3,753,358 shDecheng Capital LLC
$18.9M2,724,868 shEnavate Sciences GP, LLC
$17.0M2,459,703 shVANGUARD CAPITAL MANAGEMENT LLC
$13.0M1,876,734 shMILLENNIUM MANAGEMENT LLC
$7.9M1,143,775 shD. E. Shaw & Co., Inc.
$7.2M1,036,044 shJPMORGAN CHASE & CO
$7.0M1,012,044 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $56.5M | 8,162,897 |
| ORBIMED ADVISORS LLC | $39.4M | 5,693,589 |
| NORGES BANK | $26.1M | 3,768,619 |
| BlackRock, Inc. | $26.0M | 3,753,358 |
| Decheng Capital LLC | $18.9M | 2,724,868 |
| Enavate Sciences GP, LLC | $17.0M | 2,459,703 |
| VANGUARD CAPITAL MANAGEMENT LLC | $13.0M | 1,876,734 |
| MILLENNIUM MANAGEMENT LLC | $7.9M | 1,143,775 |
| D. E. Shaw & Co., Inc. | $7.2M | 1,036,044 |
| JPMORGAN CHASE & CO | $7.0M | 1,012,044 |
Companies Similar to UPB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Xilio Therapeutics, Inc.
Orchestra BioMed Holdings, Inc.
4D Molecular Therapeutics, Inc.
Zenas BioPharma, Inc.
CG Oncology, Inc.
PRECIGEN, INC.
Atai Beckley N.V.
Camp4 Therapeutics Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put UPB on your watchlist
Track score changes the day Upstream Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is UPB a good stock to buy?
13F Pro's AI-powered analysis of Upstream Bio, Inc. (UPB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for UPB are available on the UPB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. UPB is classified as a small company.
Which hedge funds own UPB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling UPB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Upstream Bio, Inc.'s investment landscape.